| Business Summary | | Large
Scale
Biology
Corporation
is
using
its
proteomics
and
functional
genomics
technologies
to
develop
products,
designed
to
rapidly
and
correctly
diagnose
diseases,
as
well
as
implement
safe
and
effective
personalized
treatment
therapies,
which
can
be
efficiently
delivered.
The
Company
is
focused
on
proteins,
the
fundamental
"nanomachines"
of
biology
that
carry
out
the
myriad
functions
necessary
to
keep
the
Company
alive.
Diseases
may
arise
when
made
incorrectly,
or
in
the
wrong
amounts.
All
biological
processes,
including
diseases
and
responses
to
therapeutics,
involve
changes
in
proteins.
The
Company's
technologies
are
in
three
major
areas:
Proteomics,
the
study
of
proteins
in
living
organisms;
Functional
genomics,
the
study
of
how,
when,
where
and
which
proteins
are
made
in
living
organisms,
and
Biomanufacturing,
the
production
of
proteins. | More
from
Market Guide: Expanded
Business Description |
| Financial Summary | | Large
Scale
Biology
Corp.
uses
its
proprietary
proteomics
and
functional
genomics
technologies
to
develop
products
and
establish
commercial
collaborations
with
pharmaceutical,
biotechnology,
chemical
and
other
life
sciences
companies.
For
the
six
months
ended
6/30/01,
revenues
rose
6%
to
$11.9
million.
Net
loss
rose
86%
to
$6.3
million.
Results
reflect
a
slight
increase
in
revenue
from
the
Dow
Chemical
contract,
offset
by
personnel
increases. | More
from
Market Guide: Significant
Developments |
| | | | FY2000 Pay | |
| Robert Erwin, 47 Chairman,
CEO | $184K | William Pfann, 58 CFO,
Sr. VP-Fin. | -- | David McGee, Ph.D., 51 Sr.
VP, COO, Assistant Sec. | 165K | John Rakitan, 56 Sr.
VP, Gen. Counsel, Sec. | -- | Pieter Bax, Ph.D. Sr.
VP, Corp. Devel. | -- | Dollar amounts are as of 31-Dec-2000 and compensation values are for the fiscal year ending on that date; "Pay" is salary, bonuses, etc.. |
| More
from
Market Guide on Officers & Directors: Expanded
List, Bios,
Compensation,
Options
|
|